1 DeGeorge KC,Holt HR,Hodges SC.Bladder cancer:diagnosis and treatment[J].Am Fam Physician,2017,96(8):507-514. 2 Babjuk M,Burger M,Compérat EM,et al.European association of urology guidelines on non-muscle-invasive bladder cancer(TaT1 and Carcinoma In Situ)-2019 update[J].Eur Urol,2019,76(5):639-657. 3 Malmström PU,Agrawal S,Bläckberg M,et al.Non-muscle-invasive bladder cancer:a vision for the future[J].Scand J Urol,2017,51(2):87-94. 4 Mannas MP,Lee T,Nykopp TK,et al.A risk-stratified approach to the management of high-grade T1 bladder cancer[J].Curr Opin Urol,2018,28(6):563-569. 5 Srougi V,Reis ST,Viana N,et al.Prospective evaluation of a urinary biomarker panel to detect and predict recurrence of non-muscle-invasive bladder cancer[J].World J Urol,2021,39(2):453-459. 6 Fujii Y.Prediction models for progression of non-muscle-invasive bladder cancer:a review[J].Int J Urol,2018,25(3):212-218. 7 Gregg JR,McCormick B,Wang L,et al.Short term complications from transurethral resection of bladder tumor[J].Can J Urol,2016,23(2):8198-8203. 8 Krajewski W,Moschini M,Nowak Ł,et al.Restaging transurethral resection of bladder tumours after BCG immunotherapy induction in patients with T1 non-muscle-invasive bladder cancer might not be associated with oncologic benefit[J].J Clin Med,2020,9(10):3306. 9 Schraml J,Silva JDC,Babjuk M.Current concept of transurethral resection of bladder cancer:from re-transurethral resection of bladder cancer to enbloc resection[J].Curr Opin Urol,2018,28(6):591-597. 10 Steinberg RL,Thomas LJ,O′Donnell MA.Combination intravesical chemotherapy for non-muscle-invasive bladder cancer[J].Eur Urol Focus,2018,4(4):503-505. 11 Morizane S,Honda M,Ueki M,et al.New technique of transurethral en bloc resection of bladder tumor with a flexible cystoscope and endoscopic submucosal dissection devices for the gastrointestinal tract[J].Int J Urol,2020,27(3):268-269. 12 Dug H,Jagodić S,Ahmetovi-Dug J,et al.Predicting recurrence of non-muscle-invasive bladder cancer after transurethral resection[J].Med Glas(Zenica),2016,13(1):56-61. 13 Chang DTS,Picardo A.Repeat transurethral resection is still an essential tool in treating non-muscle invasive bladder cancer:the Western Australian experience[J].Bladder(San Franc),2020,7(2):e42. 14 Zhou W,Wang W,Wu W,et al.Can a second resection be avoided after initial thulium laser endoscopic en bloc resection for non-muscle invasive bladder cancer A retrospective single-center study of 251 patients[J].BMC Urol,2020,20(1):30. 15 Lyons MD,Smith AB.Surgical bladder-preserving techniques in the management of muscle-invasive bladder cancer[J].Urol Oncol,2016,34(6):262-270. 16 Zeng XT,Liu TZ,Gong K,et al.The BPSC:A prospective study investigating the clinical effect of interventional therapy and the risk factors for bladder cancer and benign prostatic hyperplasia in Chinese population[J].J Evid Based Med,2018,11(1):64-67. 17 Raby SEM,Choudhury A.Radiotherapy for high-grade T1 bladder cancer[J].Eur Urol Focus,2018,4(4):506-508. 18 Li R,Li Y,Song J,et al.Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer:a systematic review and meta-analysis of randomized controlled trial[J].BMC Urol,2020,20(1):97. 19 Rose TL,Milowsky MI.Improving systemic chemotherapy for bladder cancer[J].Curr Oncol Rep,2016,18(5):27. 20 Haroon UM,Galvin DJ.Letter to the editor regarding the article "Meta-analysis of efficacy and safety of continuous saline bladder irrigation compared with intravesical chemotherapy after transurethral resection of bladder tumors"[J].World J Urol,2020,38(5):1343. 21 Peycelon M,Szymanski KM,Francesca Monn M,et al.Adherence with bladder irrigation following augmentation[J].J Pediatr Urol,2020,16(1):33. 22 Xia Y,Kang TW,Jung YD,et al.Sulforaphane inhibits nonmuscle invasive bladder cancer cells proliferation through suppression of HIF-1α-Mediated glycolysis in hypoxia[J].J Agric Food Chem,2019,67(28):7844-7854. 23 Efiloğlu Ö,Bayrak Ö,Turan T,et al.Thermal intravesical chemotherapy in adjuvant treatment of high risk non-muscle invasive bladder cancer.Quimioterapia intravesical térmica como tratamiento adyuvante en pacientes de cáncer de vejiga alto riesgo no-musculoinvasivos[J].Arch Esp Urol,2021,74(9):875-882. 24 Han J,Gu X,Li Y,et al.Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect[J].Biomed Pharmacother,2020,129:110393. 25 Veeratterapillay R,Heer R,Johnson MI,et al.High-risk non-muscle-invasive bladder cancer-therapy options during intravesical BCG shortage[J].Curr Urol Rep,2016,17(9):68. 26 Lammers RJ,Witjes JA,Inman BA,et al.The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer:a systematic review[J].Eur Urol,2011,60(1):81-93. 27 Aoun F,Rassy EE,Assi T,et al.Advances in urothelial bladder cancer immunotherapy,dawn of a new age of treatment[J].Immunotherapy,2017,9(5):451-460. 28 Butt SU,Malik L.Role of immunotherapy in bladder cancer:past,present and future[J].Cancer Chemother Pharmacol,2018,81(4):629-645. |